Uncover key drivers, emerging technologies, and competitive movements shaping the neonatal respiratory distress syndrome treatment market from 2026–2035 with trusted insights from The Business Research Company
What total market size is anticipated for the Neonatal Respiratory Distress Syndrome Treatment Market in 2030?
The neonatal respiratory distress syndrome treatment market size has experienced significant growth in recent years. It is projected to expand from $1.03 billion in 2025 to $1.11 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This historical expansion can be attributed to factors such as high premature birth rates, the reliance on conventional oxygen therapy, limited access to neonatal intensive care units, the early adoption of natural surfactants, and increasing infant respiratory morbidity.
The neonatal respiratory distress syndrome treatment market is projected for significant expansion over the coming years. It is anticipated to reach $1.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period is primarily driven by the advancement of synthetic surfactants, the broadening use of non-invasive ventilation technologies, increased investment in neonatal care equipment, heightened global understanding of neonatal complications, and the modernization of hospital respiratory support systems. Key trends expected during this period involve the increasing adoption of surfactant replacement therapies, a rise in the utilization of CPAP and non-invasive ventilation, improvements in neonatal intensive care infrastructure, a greater emphasis on premature birth management, and the ongoing development of synthetic and bioengineered surfactants.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20899&type=smp
What Drivers Are Influencing Production Trends In The Neonatal Respiratory Distress Syndrome Treatment Market?
The growing occurrence of premature births is anticipated to drive the expansion of the neonatal respiratory distress syndrome treatment market in the future. Premature births are defined as the delivery of babies prior to 37 weeks of gestation, leading to immature organ systems that necessitate specific medical assistance. A significant contributor to the increasing rate of premature births is the growing prevalence of maternal health issues, which can interfere with typical fetal development and induce early labor due to physiological stress on both the mother and the unborn child. Treatment for neonatal respiratory distress syndrome enhances survival rates and stabilizes premature infants, whose underdeveloped lungs make them highly susceptible to respiratory failure. As an illustration, Statistique Canada, a Canada-based governmental organization, reported in September 2024 that the percentage of births occurring before 37 weeks of gestation saw a slight increase from 8.2% in 2022 to 8.3% in 2023, reflecting a modest rise in preterm births. Consequently, the escalating incidence of premature births is fueling the expansion of the neonatal respiratory distress syndrome treatment market.
Which Segments Are Gaining Traction In The Neonatal Respiratory Distress Syndrome Treatment Market?
The neonatal respiratory distress syndrome treatment market covered in this report is segmented –
1) By Therapy: Oxygen Therapy, Surfactant Therapy
2) By Route Of Administration: Parenteral, Inhalation, Other Routes Of Administration
3) By End User: Hospitals, Sub-Acute Facilities, Home Care, Retail Pharmacies
Subsegments:
1) By Oxygen Therapy: Conventional Oxygen Therapy, High-Flow Nasal Cannula (HFNC) Oxygen Therapy, Continuous Positive Airway Pressure (CPAP) Oxygen Therapy, Invasive Mechanical Ventilation With Oxygen Therapy
2) By Surfactant Therapy: Natural Surfactants, Synthetic Surfactants, Combined Surfactant Therapy (Natural + Synthetic), Prophylactic Surfactant Therapy, Rescue Surfactant Therapy
What Trends Are Expected To Impact The Competitive Landscape Of The Neonatal Respiratory Distress Syndrome Treatment Market?
Leading companies in the neonatal respiratory distress syndrome treatment market are focusing on developing advanced solutions, such as next-generation, portable nitric-oxide delivery systems. These systems aim to improve oxygenation, minimize treatment complications, and expand access beyond traditional NICU settings. Portable nitric-oxide systems are medical devices that generate and deliver inhaled nitric oxide on demand, improving oxygenation and alleviating pulmonary hypertension in neonates with hypoxic respiratory failure, while also enabling safe use during patient transport. For instance, in June 2025, Beyond Air Inc., a US-based medical device company, submitted a PMA supplement to the U.S. Food and Drug Administration for LungFit PH 2, which is a lighter and transport-ready nitric oxide generator leveraging the company’s patented Ionizer technology. Designed for enhanced portability and convenience, this device maintains continuous nitric oxide delivery while minimizing nitrogen dioxide production, ensuring safer therapy even during neonatal transport. Concurrently, phase-4 registry data for INOmax, a well-established iNO therapy by Mallinckrodt, demonstrate continued real-world benefits in neonates with pulmonary hypertension, thereby reinforcing the clinical importance of inhaled nitric oxide in managing hypoxic respiratory failure in newborns.
Who Are The Primary Competitors In The Global Neonatal Respiratory Distress Syndrome Treatment Market?
Major companies operating in the neonatal respiratory distress syndrome treatment market are Medtronic Plc, GE Healthcare, Koninklijke Philips NV, Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Windtree Therapeutics Inc., Discovery Laboratories Inc., ResMed Inc., Abbott Laboratories, Aerogen Pharma Corp., ONY Biotech, Yuhan Corporation, Atom Medical Corporation, Mindray Bio-Medical Electronics, Getinge AB, Nihon Kohden Corporation, Siare Engineering Spa
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Neonatal Respiratory Distress Syndrome Treatment Market?
North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neonatal respiratory distress syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Neonatal Respiratory Distress Syndrome Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20899&type=smp
Browse Through More Reports Similar to the Global Neonatal Respiratory Distress Syndrome Treatment Market 2026, By The Business Research Company
Lower Respiratory Tract Therapeutics Market Report 2026
Neonatal Infant Care Market Report 2026
https://www.thebusinessresearchcompany.com/report/neonatal-infant-care-global-market-report
Acute Respiratory Distress Syndrome Ards Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model